We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.00 | 2.80 | 3.20 | 3.00 | 3.00 | 3.00 | 32,599 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.33 | 142.99M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/11/2014 07:23 | Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Appointment of Dr Daphne Tsitoura as Head of Clinical Science Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the appointment of Dr Daphne Tsitoura as Head of Clinical Science leading the Clinical Development team in Munich and Worthing from the 10th November, reporting to Professor Tim Higgenbottam. Dr Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as Principal Physician in the Respiratory Therapeutic Area in the GSKs' Stevenage Research Centre UK and has maintained a clinical link with allergy as an associate Allergist at University College Hospital London UK. Previously she has held roles of Principal Immunologist at the Institute of Biomedical Research Academy of Athens, Consultant Physician / Chief of the Allergy Unit at the Henry Dunant Hospital Athens, senior fellow in immunology and allergy at Stanford University School of Medicine Palo Alto USA, and associate professor in Respiratory Medicine College of Physicians and Surgeons Columbia University New York. Tim Higenbottam, R & D Director said: "With an impressive career in medicine development and allergy, Daphne brings to Allergy Therapeutics a passion and drive to enhance the ease of use of allergy vaccines. She has a great depth of understanding of the therapeutic methods of modulation of the innate immune system to optimise allergy therapies. Her expertise will lend enormous support and strengthen our team of pharmaceutical experts and drive the research to gain approval of our Pollinex Quattro ultra-short course allergy vaccines in Europe and US." | jimmyloser | |
04/11/2014 07:13 | Well its certainly an interesting appointment. However, I can't help but think its in response to the last couple of years impasse especially in the US where little appears to have happened since the clinical trial hold was lifted. Hopefully this will drive things forward. but you have to wonder at what pace? Still lots of potential here but they need to crack-on and deliver before somebody else beats them to it | audigger | |
27/10/2014 07:49 | I find the note to editors interesting with its recently changed wording. Note the use of the words and context of 'infrastructure' and 'distributors' and how expansion into emerging markets (USA?) is with 'infrastructure' and not 'distributors'! impo/dyor Notes to editors About Allergy Therapeutics Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets. | jimmyloser | |
23/10/2014 15:48 | Interesting little jump today! | audigger | |
16/10/2014 16:13 | Seems to be a familiar pattern with AGY. | audigger | |
16/10/2014 09:59 | Hardly "glowing int he dark" at the moment eh Cube.Slightly disappointing downward motion. | algernon2 | |
07/10/2014 15:33 | Cube, I agree. It was interesting that they only issued positive noises on the USA though. How do you view the presence of Abbott on the scene? | jimmyloser | |
07/10/2014 13:10 | Back to normal! no news with results and down we go!. Need the US deal or the same pattern every 6 months..GLA ;0)) | cube boss | |
06/10/2014 07:12 | Not long for Allergy as we know it Jim?? | jimmyloser | |
02/10/2014 17:16 | No problem with that, but why drop reference to the GBP45.7 million figure? Of course, a higher figure would be good,. | farmer george | |
02/10/2014 16:46 | It means that they are signalling that they are ramping up in the USA as I read it. I am not ramping up though. lol, Patience as the Cube would say. | jimmyloser | |
02/10/2014 16:27 | ...does that mean the earlier cited number of GBP45.7 million will be under-shot or, indeed, exceeded? We wait. | farmer george | |
02/10/2014 14:54 | The Company is expanding its infrastructure into the Emerging Markets. | jimmyloser | |
02/10/2014 14:52 | Hmmmm...no forecast for 2014? | farmer george | |
02/10/2014 14:34 | This was September 4th 2014 Notes to editors About Allergy Therapeutics Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with expected revenue of GBP45.7million, before milestones and rebates and supported by a foreign exchange benefit of GBP2.3million, an increase of 14% on the previous year (2013:GBP39.9milllio This was this week - spot the important difference Notes to editors About Allergy Therapeutics Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of almost GBP40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets. | jimmyloser | |
01/10/2014 14:50 | It will be very interesting to see if these loose shares are mopped up later! | jimmyloser | |
30/9/2014 20:30 | Manuel Llobet said "creating value for ......'all'..... our shareholders." | jimmyloser | |
30/9/2014 08:24 | That's what I thought, it's unlikely now that they'll be enough stock out there to send the price up and those that have the stock can influence the price with timing of events etc. Could it now be that the stock we're sat on doesn't amount to sufficient for them to worry about? Will they want to claw back all the stock before investing in the future or announcing the future? | aruntim | |
30/9/2014 07:58 | THIS IS PURE CONJECTURE ON MY PART. It appears that Allergy now have a major new shareholder in Abbott. It's my guess and a guess only that it is Abbott who are keeping our share price where it is and are picking up every share that they can get their hands on at best price. Is it a poison chalice for Allergy and for us this takeover of CFR?. I personally cant see any independent future now for Allergy. Their future looks to be part of a bigger group. No prizes for guessing which group! 40p per share by Christmas. impo/pure conjecture/dyor etc etc | jimmyloser | |
30/9/2014 07:47 | What's happened now, any chance of a Twitter style 140 character summary? | aruntim | |
25/9/2014 16:34 | Every single share IS wanted.... I rest my case. 100,000 @ 24.625 You sell 'em and they will buy them. A brilliant report earlier this week. impo | jimmyloser | |
25/9/2014 07:46 | More late 75K trades yday. Looks like they were both sells hence the drop this am. I think we may see a small pull back and then a jumpt back to 30. Time will tell! | audigger |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions